DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Spiriva (Tiotropium Bromide Monohydrate Inhalation) - Summary



(tiotropium bromide inhalation powder)

Tiotropium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M1 to M5. SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) consists of a capsule dosage form containing a dry powder formulation of SPIRIVA (tiotropium bromide) intended for oral inhalation only with the HandiHaler inhalation device.

SPIRIVA HandiHaler is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

See all Spiriva indications & dosage >>


Media Articles Related to Spiriva (Tiotropium Inhalation)

Spiriva® (tiotropium) Respimat® becomes the only long-acting muscarinic-antagonist licensed in asthma care
Source: Respiratory / Asthma News From Medical News Today [2014.10.02]
Boehringer Ingelheim announced today that adult asthma patients could benefit from a new treatment.

FDA OKs Spiriva Respimat for COPD
Source: MedPage Today Allergy & Immunology [2014.09.25]
(MedPage Today) -- Approval of mist formulation follows support from advisory panel.

more news >>

Published Studies Related to Spiriva (Tiotropium Inhalation)

Acute effects of indacaterol on lung hyperinflation in moderate COPD: A comparison with tiotropium. [2012.01]
BACKGROUND: Evidence has been provided that high-dose indacaterol (300 mug) can reduce lung hyperinflation in moderate-to-severe chronic obstructive pulmonary disease (COPD). AIM: To study whether low-dose indacaterol (150 mug) also reduces lung hyperinflation in comparison with the recommended dose of tiotropium (18 mug) in moderate COPD... CONCLUSIONS: Low-dose indacaterol has a bronchodilator effect that is similar to the recommended dose of tiotropium, but it is slightly superior in reducing lung hyperinflation. TRIAL REGISTRATION: ClinicalTrials.gov number: NCT00999908. Copyright (c) 2011 Elsevier Ltd. All rights reserved.

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. [2011.08]
BACKGROUND: The efficacy and safety of inhaled long-acting beta(2)-adrenergic agonists in asthmatic patients with the B16-Arg/Arg genotype has been questioned, and the use of antimuscarinics has been proposed as an alternative in patients whose symptoms are not controlled by inhaled corticosteroids (ICSs). OBJECTIVE: We compared the efficacy and safety of the long-acting anticholinergic tiotropium with salmeterol and placebo added to an ICS in B16-Arg/Arg patients with asthma that was not controlled by ICSs alone... CONCLUSION: Tiotropium was more effective than placebo and as effective as salmeterol in maintaining improved lung function in B16-Arg/Arg patients with moderate persistent asthma. Safety profiles were comparable. Copyright (c) 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. [2011.08]
BACKGROUND: Some patients with severe asthma remain symptomatic and obstructed despite maximal recommended treatment. Tiotropium, a long-acting inhaled anticholinergic agent, might be an effective bronchodilator in such patients. OBJECTIVE: We sought to compare the efficacy and safety of 2 doses of tiotropium (5 and 10 mug daily) administered through the Respimat inhaler with placebo as add-on therapy in patients with uncontrolled severe asthma (Asthma Control Questionnaire score, >/= 1.5; postbronchodilator FEV, </= 80% of predicted value) despite maintenance treatment with at least a high-dose inhaled corticosteroid plus a long-acting beta-agonist... CONCLUSION: The addition of once-daily tiotropium to asthma treatment, including a high-dose inhaled corticosteroid plus a long-acting beta-agonist, significantly improves lung function over 24 hours in patients with inadequately controlled, severe, persistent asthma. Copyright (c) 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. [2011.07]
BACKGROUND AND OBJECTIVE: Studies in respiratory diseases other than chronic obstructive pulmonary disease suggest potentially differing responses to medications among patients from different regions. We report a subgroup analysis of patients recruited to Asian centres from a previously reported 4-year COPD trial... CONCLUSIONS: In COPD patients from Asia, tiotropium improves lung function, improves health-related quality of life and reduces exacerbations over 4 years of treatment. (c) 2011 The Authors; Respirology (c) 2011 Asian Pacific Society of Respirology.

Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD. [2011.06]
BACKGROUND: Lung mucociliary clearance is impaired in patients with chronic obstructive pulmonary disease (COPD). Treatment guidelines recommend that patients with COPD receive maintenance therapy with long-acting beta-agonists and anticholinergic agents... CONCLUSION: Formoterol (12 mug) enhances mucus clearance in patients with mild to moderate COPD when given as a single dose, and may do so when given for 14 days. Studies of longer duration would be needed in order to assess the effects of the study drugs on mucus clearance when they are used for long-term maintenance therapy. Copyright (c) 2011. Published by Elsevier Ltd.

more studies >>

Clinical Trials Related to Spiriva (Tiotropium Inhalation)

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD [Completed]

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD [Completed]

A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma [Recruiting]
Rationale for the current trial is to demonstrate 24 hour bronchodilator efficacy and safety of tiotropium 5 µg administered once daily (in the evening) which is regarded beneficial for the compliance and convenience of the patient in comparison to placebo. Further the rationale is to evaluate efficacy and safety of tiotropium 2. 5 µg administered twice daily delivered by the Respimat® inhaler in comparison to placebo and tiotropium 5 µg administered once daily (in the evening) delivered by the Respimat® inhaler in patients with moderate persistent asthma.

Rationale for the pharmacokinetic subinvestigation is to evaluate the 24 hours exposure to tiotropium in patients with moderate persistent asthma when administered 5 µg tiotropium once daily (in the evening) or 2. 5 µg tiotropium twice daily.

Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva [Completed]
To evalute acute effect of single dose of ipratropium (Atrovent) or fenoterol (Berotec) in comparison to placebo when given to COPD patients on pharmacodynamic steady state of tiotropium (Spiriva)

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) [Recruiting]
The primary objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components (tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with COPD.

more trials >>

Reports of Suspected Spiriva (Tiotropium Inhalation) Side Effects

Incorrect Route of Drug Administration (1887)Dyspnoea (640)Drug Ineffective (271)DRY Mouth (140)Pneumonia (131)Cough (119)Chronic Obstructive Pulmonary Disease (111)Bronchitis (79)Death (70)Chest Discomfort (68)more >>


Based on a total of 1 ratings/reviews, Spiriva has an overall score of 9. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.

Spiriva review by 57 year old female patient

Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   Asthma
Dosage & duration:   1 puff (dosage frequency: bid) for the period of current
Other conditions:   Bronchitis
Other drugs taken:   Symbicort
Reported Results
Benefits:   I used to live on my MDI(combivent). I started maintenance drugs Spiriva and Symbicort and it has changed my world. I, on adverage, dont have to take my MDI at all anymore. I have my days that I have to, living in Texas can be a nightmare of allergies. I can do more activities without feeling so short of breath. I have not had any major side effects yet...Overall after starting Spiriva I'm doing much better. For anyone with Asthma I would suggest they try this drug.
Side effects:   I have really had no major side effects yet. Maybe, if any, a headache and I'm not sure that is one?
Comments:   Well, theres not a whole lot to say about the treatment details. I take one dose per day in the morning. Its a dry disk powder that you inhale. Its very easy, quick, and seems to work very fast.

See all Spiriva reviews / ratings >>

Page last updated: 2014-10-02

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014